Research > Targeting cancer
Polymer-drug conjugates to target specific cancer markers
Polymer–drug conjugates that can actively target the tumor microenvironment have emerged as an attractive technology for improving the therapeutic efficacy of cytotoxic drugs. In addition to the drug, these polymers possess new cell targeting ligands specific for markers uniquely expressed on cells at the disease site. Several polymers made from different materials have been designed and evaluated by our laboratory to target different cell types in the tumor microenvironment.
Polymer backbone bearing an E-selectin-binding peptide (Esbp) and doxorubicin (DOX), binding activated tumor endothelial cells, followed by drug internalization and tumor/metastasis regression (Shamay Y, et al., J. Control Release 2015, Rütter M. et al., Nano Today 2024)
Our tumor vasculature-targeted technology was licensed to Vaxil Bio Pharmaceutics for further development. Read more
